查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401859

2030 年藥物基因組學市場預測：按配銷通路、技術、應用、最終用戶和地區分類的全球分析

Pharmacogenomics Market Forecasts to 2030 - Global Analysis By Distribution Channel, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球藥物基因組學市場規模為 166.6 億美元，預計預測期內複合年成長率為 11.1%，到 2030 年將達到 348.1 億美元。

透過分析影響個體對特定藥物反應的人類遺傳變異來開發藥物的研究稱為藥物基因組學。這種方法對於精準醫學至關重要，可以根據遺傳標記提供個人化治療計畫。改善患者治療效果、減少副作用、提高藥物療效並提供更具成本效益的醫療保健至關重要。

根據美國癌症研究所2020年9月發布的資料，預計2020年美國將有1,806,590人新診斷出癌症，606,520人將死於癌症。

個人化醫療的普及

個人化醫療是一種根據個人的遺傳、基因組和臨床特徵量身訂做醫療照護的方法。透過客製化醫療介入措施，我們的目標是最大限度地提高治療效果、最大限度地減少副作用並改善患者的治療結果。隨著患者和醫療保健提供者越來越意識到藥物基因組學的潛在益處，對基因檢測和個體化治療計劃的需求正在增加。此外，製藥公司也投資基於基因組資料的標靶治療。患者需求、臨床相關性和產業創新的融合正在推動藥物基因組學市場的成長。

成本壁壘

成本障礙是藥物基因體學市場的主要抑制因素。基因檢測和藥物基因組學服務價格昂貴，使得許多患者和醫療系統無法獲得這些服務。 核酸定序、資料分析和解釋的高成本可能會限制藥物基因組學的採用，特別是在資源有限的環境中。這些經濟負擔導致無法平等地獲得個人化醫療的好處，並加劇了醫療保健差距。

基因檢測技術的進展

基因檢測的進步可以透過降低成本、提高可及性和擴大檢測的可用性來刺激成長。隨著科技的進步，基因檢測變得更加可用、更便宜且更準確。此外，方便用戶使用的家庭檢測套組和行動健康應用程式的開發使患者和醫療保健專業人員的測試過程變得更加容易。此外，這些發展不僅簡化了個體遺傳資訊的可用性，而且還促進將藥物基因組資料涵蓋標準治療方案。基因檢測的廣泛普及使得藥物基因組學市場佔有率的擴大和個人化醫療的廣泛採用成為可能。

資料隱私和安全

遺傳資訊高度敏感，處理不當或詐欺存取該資料可能會導致隱私侵犯、資訊盜竊和歧視。由於擔心潛在的濫用，患者可能不願意接受基因檢測或共用資料。此外，保護遺傳資訊的法律規範不斷發展，可能為醫療保健提供者和製藥公司帶來合規挑戰。因此，導致市場成長下降。

COVID-19 的影響

COVID-19 的爆發對市場產生了多方面的影響。一方面，它加速了數位醫療的普及，包括遠端醫療和遠端監控，可以透過促進資料共用和患者諮詢來補充藥物基因組學。大流行的緊迫性也導致醫療保健和製藥領域的研究和投資增加，這可能會刺激藥物基因組學的進步。然而，也有負面影響。許多醫療保健資源和研究工作都針對 COVID-19，這可能會減緩藥物基因組學計劃的進展。由於封鎖和安全問題，藥物基因組治療的臨床試驗可能會被推遲或中斷。

DNA定序部分預計將成為預測期內最大的部分

預計DNA定序部分將佔最大佔有率。 DNA定序涉及確定個體基因組中 DNA 鹼基的確切順序。透過分析遺傳變異，研究人員和醫療保健提供者可以識別與藥物反應和疾病感受性相關的特定基因和遺傳標記。這些資訊允許治療方法客製化，並確保為患者提供最有效和最安全的治療方法選擇。此外，次世代定序等DNA測序技術的進步使得基因組資料的獲取速度更快、更具成本效益，推動了這一領域的成長，並增加了藥物基因組學在醫療保健領域的潛在應用。

醫院和診所領域預計在預測期內複合年成長率最高。

預計醫院和診所部門在預測期內將出現良好的成長。醫療機構利用藥物基因組學測試來定製藥物治療計劃，並確保藥物對個別患者有效且安全。藥物基因組學幫助臨床醫生確定最合適的藥物治療和給藥，最大限度地減少副作用並最佳化患者的治療結果。此外，它還可以幫助選擇從癌症到心血管疾病等多種疾病的治療方法。隨著個人化醫療需求的增加，醫院和診所必須將藥物基因組學涵蓋日常臨床實踐，透過提供個體化、資料主導的治療計劃來徹底改變醫療保健。

佔有率最大的地區

在估計期間，亞太地區佔據最大的市場佔有率。亞太地區是藥物基因體學的重要且快速成長的市場。該地區面臨著癌症、心血管疾病和糖尿病等慢性疾病日益沉重的負擔，推動了對個人化醫療和藥物基因組學解決方案的需求。中國、日本和韓國等亞太地區國家正在大力投資基因組學研究，在了解影響藥物反應和疾病的遺傳因素方面取得了重大進展。

複合年成長率最高的地區：

預計北美在預測期內將實現盈利成長。北美擁有先進的醫療保健系統，包括成熟的醫院、研究機構和製藥公司，為藥物基因組學的發展提供了堅實的基礎。美國FDA 等監管機構正在積極認知到藥物基因組學在藥物開發、核准和標籤中的重要性，這正在加速採用。此外，北美製藥公司正在藥物基因組學方面投入巨資，從而開發了許多個體化治療方法。該地區處於藥物基因組學研究的前沿，在基因組研究、臨床試驗和標靶治療開發方面進行了大量投資。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球藥物基因體學市場：按配銷通路

  • 醫院藥房
  • 零售藥房
  • 線上藥房

第6章全球藥物基因體學市場：依技術分類

  • DNA序列測定
  • 聚合酶鍊式反應
  • 微陣列
  • 質譜
  • 電泳

第7章全球藥物基因體學市場：依應用分類

  • 藥物研發
  • 腫瘤學
  • 神經病學
  • 疼痛管理
  • 心血管疾病
  • 精神病學
  • 感染疾病
  • 其他用途

第8章全球藥物基因組學市場：依最終用戶分類

  • 醫院和診所
  • 研究和學術機構
  • 其他最終用戶

第9章全球藥物基因體學市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • Novartis AG
  • Ferndale Pharma Group, Inc.
  • Mylan NV
  • F. Hoffmann-La Roche Ltd
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • AstraZeneca
  • Merck & Co., Inc.
  • Eli Lilly and Company
  • Sun Pharmaceutical Industries Ltd.
  • Lupin
  • NATCO Pharma Limited
  • Teva Pharmaceutical Industries Ltd
  • AbbVie Inc.
  • Boehringer Ingelheim International GmbH
  • Abbott
  • Bayer AG
  • Thermo Fisher Scientific, Inc.
  • Admera Health
  • Agilent Technologies
Product Code: SMRC24379

According to Stratistics MRC, the Global Pharmacogenomics Market is accounted for $16.66 billion in 2023 and is expected to reach $34.81 billion by 2030 growing at a CAGR of 11.1% during the forecast period. The study of developing drugs by analysing genetic variations in humans that affect an individual's response to a particular drug is known as pharmacogenomics. This approach is vital for precision medicine, offering personalised treatment plans based on genetic markers. It is essential to improving patient outcomes, reducing adverse drug reactions, enhancing medication efficacy, and providing more cost-effective healthcare.

According to data published by National Cancer Institute in September 2020, stated that an estimated 1,806,590 new cases of cancer will be diagnosed in the U.S. and 606,520 people will die from the disease in 2020.

Market Dynamics:

Driver:

Increasing adoption of personalized medicine

Personalised medicine is an approach that tailors medical treatments to an individual's genetic, genomic, and clinical characteristics. It aims to maximise treatment effectiveness, minimise side effects, and improve patient outcomes by customising healthcare interventions. As patients and healthcare providers become more aware of the potential benefits of pharmacogenomics, the demand for genetic testing and personalised treatment plans is on the rise. Furthermore, pharmaceutical companies are also investing in targeted therapies based on genomic data. This convergence of patient demand, clinical relevance, and industry innovation is propelling the growth of the pharmacogenomics market.

Restraint:

Cost barriers

Cost barriers pose a significant restraint on the Pharmacogenomics market. Genetic testing and pharmacogenomic services can be expensive, making them inaccessible to many patients and healthcare systems. The high costs of DNA sequencing, data analysis, and interpretation can limit the adoption of pharmacogenomics, especially in resource-constrained environments. This financial burden can result in unequal access to the benefits of personalised medicine, exacerbating healthcare disparities.

Opportunity:

Advancements in genetic testing technologies

Developments in genetic testing can spur growth by lowering the cost, increasing accessibility, and expanding the availability of testing. Genetic testing is getting easier to obtain, less expensive, and more accurate as technology advances. Furthermore, the process is made easier for patients and healthcare professionals by the creation of user-friendly at-home testing kits and mobile health applications. Moreover, these developments not only simplify genetic information availability for individuals but also make it easier to incorporate pharmacogenomic data into standard therapeutic procedures. Growing pharmacogenomics market share and wider adoption of personalised medicine are made possible by the increasing prevalence of genetic testing.

Threat:

Data privacy and security

Genetic information is highly sensitive, and the mishandling or unauthorised access to this data could lead to privacy breaches, identity theft, or discrimination. Patients may be hesitant to undergo genetic testing or share their data, fearing potential misuse. Furthermore, regulatory frameworks for safeguarding genetic information are continually evolving and can create compliance challenges for healthcare providers and pharmaceutical companies. Hence, it will lead to a decrease in market growth.

COVID-19 Impact

The COVID-19 pandemic has had a multifaceted impact on the market. On one hand, it accelerated the adoption of digital health, including telehealth and remote monitoring, which can complement pharmacogenomics by facilitating data sharing and patient consultations. The urgency of the pandemic also led to increased research and investment in healthcare and pharmaceuticals, potentially driving advancements in pharmacogenomics. However, there were negative effects as well. Many healthcare resources and research efforts were redirected toward COVID-19, potentially slowing the progress of pharmacogenomics projects. Clinical trials for pharmacogenomic therapies may have been delayed or disrupted due to lockdowns and safety concerns.

The DNA Sequencing segment is expected to be the largest during the forecast period

The DNA Sequencing segment is estimated to hold the largest share. DNA sequencing involves determining the precise order of DNA bases in an individual's genome. By analysing genetic variations, researchers and healthcare providers can identify specific genes and genetic markers relevant to drug response and disease susceptibility. This information enables the customization of medical treatments, ensuring the most effective and safe therapeutic options for patients. In addition, advances in DNA sequencing technologies, such as next-generation sequencing, have made it faster and more cost-effective to obtain genomic data, driving the growth of this segment and expanding the potential applications of pharmacogenomics in healthcare.

The Hospitals & Clinics segment is expected to have the highest CAGR during the forecast period

The Hospitals & Clinics segment is anticipated to have lucrative growth during the forecast period. The healthcare facilities utilise pharmacogenomic testing to customise drug treatment plans, ensuring that medications are both effective and safe for individual patients. Pharmacogenomics can help clinicians identify the most suitable drug therapies and dosages, minimising adverse reactions and optimising patient outcomes. Furthermore, it aids in the selection of treatments for various medical conditions, from cancer to cardiovascular diseases. As the demand for personalised medicine grows, hospitals and clinics are essential in integrating pharmacogenomics into routine clinical practice, revolutionising healthcare by providing individualised, data-driven treatment plans.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period. The Asia-Pacific region is a significant and rapidly growing market for pharmacogenomics. The region faces a rising burden of chronic diseases, including cancer, cardiovascular diseases, and diabetes, which has led to a growing demand for personalised medicine and pharmacogenomic solutions. Countries in the Asia-Pacific region, such as China, Japan, and South Korea, have made substantial investments in genomics research, leading to significant advancements in understanding genetic factors influencing drug responses and diseases.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. North America boasts advanced healthcare systems, including well-established hospitals, research institutions, and pharmaceutical companies, providing a solid foundation for the growth of pharmacogenomics. Regulatory agencies, such as the FDA in the United States, have been proactive in recognising the importance of pharmacogenomics in drug development, approval, and labelling, which accelerates its adoption. Furthermore, North American pharmaceutical companies have heavily invested in pharmacogenomics, resulting in the development of numerous personalised therapies. The region is at the forefront of pharmacogenomic research, with substantial investments in genomic studies, clinical trials, and the development of targeted therapies.

Key players in the market:

Some of the key players in the Pharmacogenomics Market include Novartis AG, Ferndale Pharma Group, Inc., Mylan N.V., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Pfizer Inc., AstraZeneca, Merck & Co., Inc., Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Lupin, NATCO Pharma Limited, Teva Pharmaceutical Industries Ltd, AbbVie Inc., Boehringer Ingelheim International GmbH, Abbott, Bayer AG, Thermo Fisher Scientific, Inc., Admera Health and Agilent Technologies.

Key Developments:

In October 2023, Novartis, a global leader in immuno-dermatology and rheumatology, announced that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of HS.2

In October 2023, Pfizer Inc. and BioNTech SE announced positive topline results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age.

In October 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved PENBRAYA (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent vaccine that provides coverage against the most common serogroups causing meningococcal disease in adolescents and young adults 10 through 25 years of age.

Distribution Channels Covered:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Technologies Covered:

  • DNA Sequencing
  • Polymerase Chain Reaction
  • Microarray
  • Mass Spectrometry
  • Electrophoresis

Applications Covered:

  • Drug Discovery
  • Oncology
  • Neurology
  • Pain Management
  • Cardiovascular diseases
  • Psychiatry
  • Infectious diseases
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Research Institutions and Academic Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Pharmacogenomics Market, By Distribution Channel

  • 5.1 Introduction
  • 5.2 Hospital Pharmacy
  • 5.3 Retail Pharmacy
  • 5.4 Online Pharmacy

6 Global Pharmacogenomics Market, By Technology

  • 6.1 Introduction
  • 6.2 DNA Sequencing
  • 6.3 Polymerase Chain Reaction
  • 6.4 Microarray
  • 6.5 Mass Spectrometry
  • 6.6 Electrophoresis

7 Global Pharmacogenomics Market, By Application

  • 7.1 Introduction
  • 7.2 Drug Discovery
  • 7.3 Oncology
  • 7.4 Neurology
  • 7.5 Pain Management
  • 7.6 Cardiovascular diseases
  • 7.7 Psychiatry
  • 7.8 Infectious diseases
  • 7.9 Other Applications

8 Global Pharmacogenomics Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Research Institutions and Academic Institutes
  • 8.4 Other End Users

9 Global Pharmacogenomics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Novartis AG
  • 11.2 Ferndale Pharma Group, Inc.
  • 11.3 Mylan N.V.
  • 11.4 F. Hoffmann-La Roche Ltd
  • 11.5 Takeda Pharmaceutical Company Limited
  • 11.6 Pfizer Inc.
  • 11.7 AstraZeneca
  • 11.8 Merck & Co., Inc.
  • 11.9 Eli Lilly and Company
  • 11.10 Sun Pharmaceutical Industries Ltd.
  • 11.11 Lupin
  • 11.12 NATCO Pharma Limited
  • 11.13 Teva Pharmaceutical Industries Ltd
  • 11.14 AbbVie Inc.
  • 11.15 Boehringer Ingelheim International GmbH
  • 11.16 Abbott
  • 11.17 Bayer AG
  • 11.18 Thermo Fisher Scientific, Inc.
  • 11.19 Admera Health
  • 11.20 Agilent Technologies

List of Tables

  • Table 1 Global Pharmacogenomics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 3 Global Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 4 Global Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 5 Global Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 6 Global Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 7 Global Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
  • Table 8 Global Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
  • Table 9 Global Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
  • Table 10 Global Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • Table 11 Global Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
  • Table 12 Global Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
  • Table 13 Global Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
  • Table 14 Global Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 15 Global Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 16 Global Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 17 Global Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
  • Table 18 Global Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
  • Table 19 Global Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
  • Table 20 Global Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 21 Global Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
  • Table 22 Global Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 23 Global Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
  • Table 24 Global Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 25 North America Pharmacogenomics Market Outlook, By Country (2021-2030) ($MN)
  • Table 26 North America Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 27 North America Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 28 North America Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 29 North America Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 30 North America Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 31 North America Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
  • Table 32 North America Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
  • Table 33 North America Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
  • Table 34 North America Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • Table 35 North America Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
  • Table 36 North America Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
  • Table 37 North America Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
  • Table 38 North America Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 39 North America Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 40 North America Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 41 North America Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
  • Table 42 North America Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
  • Table 43 North America Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
  • Table 44 North America Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 45 North America Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
  • Table 46 North America Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 47 North America Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
  • Table 48 North America Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 49 Europe Pharmacogenomics Market Outlook, By Country (2021-2030) ($MN)
  • Table 50 Europe Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 51 Europe Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 52 Europe Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 53 Europe Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 54 Europe Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 55 Europe Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
  • Table 56 Europe Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
  • Table 57 Europe Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
  • Table 58 Europe Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • Table 59 Europe Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
  • Table 60 Europe Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
  • Table 61 Europe Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
  • Table 62 Europe Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 63 Europe Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 64 Europe Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 65 Europe Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
  • Table 66 Europe Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
  • Table 67 Europe Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
  • Table 68 Europe Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 69 Europe Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
  • Table 70 Europe Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 71 Europe Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
  • Table 72 Europe Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 73 Asia Pacific Pharmacogenomics Market Outlook, By Country (2021-2030) ($MN)
  • Table 74 Asia Pacific Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 75 Asia Pacific Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 76 Asia Pacific Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 77 Asia Pacific Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 78 Asia Pacific Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 79 Asia Pacific Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
  • Table 80 Asia Pacific Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
  • Table 81 Asia Pacific Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
  • Table 82 Asia Pacific Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • Table 83 Asia Pacific Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
  • Table 84 Asia Pacific Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
  • Table 85 Asia Pacific Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
  • Table 86 Asia Pacific Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 87 Asia Pacific Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 88 Asia Pacific Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 89 Asia Pacific Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
  • Table 90 Asia Pacific Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
  • Table 91 Asia Pacific Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
  • Table 92 Asia Pacific Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 93 Asia Pacific Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
  • Table 94 Asia Pacific Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 95 Asia Pacific Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
  • Table 96 Asia Pacific Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 97 South America Pharmacogenomics Market Outlook, By Country (2021-2030) ($MN)
  • Table 98 South America Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 99 South America Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 100 South America Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 101 South America Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 102 South America Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 103 South America Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
  • Table 104 South America Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
  • Table 105 South America Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
  • Table 106 South America Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • Table 107 South America Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
  • Table 108 South America Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
  • Table 109 South America Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
  • Table 110 South America Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 111 South America Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 112 South America Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 113 South America Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
  • Table 114 South America Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
  • Table 115 South America Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
  • Table 116 South America Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 117 South America Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
  • Table 118 South America Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 119 South America Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
  • Table 120 South America Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 121 Middle East & Africa Pharmacogenomics Market Outlook, By Country (2021-2030) ($MN)
  • Table 122 Middle East & Africa Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 123 Middle East & Africa Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 124 Middle East & Africa Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 125 Middle East & Africa Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 126 Middle East & Africa Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 127 Middle East & Africa Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
  • Table 128 Middle East & Africa Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
  • Table 129 Middle East & Africa Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
  • Table 130 Middle East & Africa Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • Table 131 Middle East & Africa Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
  • Table 132 Middle East & Africa Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
  • Table 133 Middle East & Africa Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
  • Table 134 Middle East & Africa Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 135 Middle East & Africa Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 136 Middle East & Africa Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 137 Middle East & Africa Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
  • Table 138 Middle East & Africa Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
  • Table 139 Middle East & Africa Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
  • Table 140 Middle East & Africa Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 141 Middle East & Africa Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
  • Table 142 Middle East & Africa Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 143 Middle East & Africa Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
  • Table 144 Middle East & Africa Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)